Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Tentative Approval for Efinaconazole Topical Solution, 10%.

Tuesday April 13, 2021 at 2:14 pm

Alembic Pharmaceuticals announces its joint venture Aleor Dermaceuticals receives USFDA Tentative Approval for Efinaconazole Topical Solution, 10%. Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Efinaconazole Topical Solution, 10%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch). Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole Topical Solution, 10% has an estimated market size of US$ 233 million for twelve months ending December 2020 according to IQVIA. Aleor has settled the case with Bausch Health and. will launch its generic as per the terms of the settlement. Alembic has a cumulative total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.

Releted Blog
  • 5 Tips to Healthy Your Gut This Summer Season

    5 Tips to Healthy Your Gut This Summer Season Summer time can be a very stressful time for the gut and the gut has a lot of things to handle during...

  • Red beet juice good for you?

    Is red beet juice good for you? Red beet juice is it really good, isn't it? The nutrient-rich and vivid red beet juice is a very tempting choice fo...

  • Summer Season: Avoid These 5 Foods to Stay Healthy!

    During the summer, the air is usually hot and the body is producing more sweat which is why is it so important to stay hydrated. In addition to drinki...